Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C10H13NO2.ClH |
| Molecular Weight | 215.677 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(N)CC1=CC2=C(OCO2)C=C1
InChI
InChIKey=XLAOKZDOZHZWBK-UHFFFAOYSA-N
InChI=1S/C10H13NO2.ClH/c1-7(11)4-8-2-3-9-10(5-8)13-6-12-9;/h2-3,5,7H,4,6,11H2,1H3;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C10H13NO2 |
| Molecular Weight | 179.2157 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Tenamfetamine (also known as 3,4-methylenedioxyamphetamine (or MDA)) is a hallucinogen that acts as a serotonergic 5-HT2A receptor agonist and releases monoamines by interacting with monoamine plasmalemmal transporters. Tenamfetamine had no accepted medical use and it was scheduled as a controlled substance in the US in 1970. Despite appearing in illicit drug preparations, tenamfetamine has not been studied in humans in over 30 years. In 2010 was published article where was described the action of tenamfetaminea in a clinical trial in humans. In this trial was shown that the drug had induced mystical-type experiences and, in at least some individuals, closed-eye visions. However, during that experiment were impossible to provide strong evidence for changes in the efficacy of top-down influences on perception or acutely increased occipital cortex excitation.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans. | 2001 Aug |
|
| Delayed rhabdomyolysis after ecstasy use. | 2001 Jan |
|
| An exploration of the history and controversies surrounding MDMA and MDA. | 2001 Jul-Sep |
|
| Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans. | 2002 |
|
| Automated headspace solid-phase dynamic extraction for the determination of amphetamines and synthetic designer drugs in hair samples. | 2002 Jun 7 |
|
| Rewarding effects of the optical isomers of 3,4-methylenedioxy-methylamphetamine ('Ecstasy') and 3,4-methylenedioxy-ethylamphetamine ('Eve') measured by conditioned place preference in rats. | 2002 Sep 27 |
|
| Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect? | 2002 Sep 27 |
|
| Developmental 3,4-methylenedioxymethamphetamine (MDMA) impairs sequential and spatial but not cued learning independent of growth, litter effects or injection stress. | 2003 Apr 4 |
|
| Methylenendioxyamphetamine produces serotonin nerve terminal loss and diminished behavioural and neurochemical responses to the antidepressant fluoxetine. | 2003 Aug |
|
| Enantioselective quantitation of the ecstasy compound (R)- and (S)-N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma and urine. | 2003 Aug 15 |
|
| Actions of amphetamine derivatives and cathinone at the noradrenaline transporter. | 2003 Aug 22 |
|
| Direct screening of urine for MDMA and MDA by liquid chromatography-tandem mass spectrometry. | 2003 Jan-Feb |
|
| Is the Ecstasy-induced ipsilateral rotation in 6-hydroxydopamine unilaterally lesioned rats dopamine independent? | 2003 Jul |
|
| Confirmation of amphetamine, methamphetamine, MDA and MDMA in urine samples using disk solid-phase extraction and gas chromatography-mass spectrometry after immunoassay screening. | 2003 Jul 25 |
|
| Fatality due to combined use of the designer drugs MDMA and PMA: a distribution study. | 2003 Jul-Aug |
|
| 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. | 2003 Jun |
|
| Chiral separation of 3,4-methylenedioxymeth- amphetamine and related compounds in clandestine tablets and urine samples by capillary electrophoresis/fluorescence spectroscopy. | 2003 Mar |
|
| Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats. | 2003 Sep-Oct |
|
| Surface-activated chemical ionization ion trap mass spectrometry in the analysis of amphetamines in diluted urine samples. | 2004 |
|
| High-performance liquid chromatography with fluorescence detection for the simultaneous determination of 3,4-methylenedioxymethamphetamine, methamphetamine and their metabolites in human hair using DIB-Cl as a label. | 2004 Apr |
|
| Application of ORAL.screen saliva drug test for the screening of methamphetamine, MDMA, and MDEA incorporated in hair. | 2004 Mar |
|
| Reference materials for analytical toxicology including doping control: freeze-dried urine samples. | 2004 May |
|
| Effectiveness of multiple internal standards: deuterated analogues of methylenedioxymethamphetamine, methylenedioxyamphetamine, methamphetamine, and amphetamine. | 2004 Nov-Dec |
|
| Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). | 2004 Sep |
|
| Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. | 2005 Apr |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:46:42 GMT 2023
by
admin
on
Fri Dec 15 15:46:42 GMT 2023
|
| Record UNII |
8929NLK7WN
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID1049017
Created by
admin on Fri Dec 15 15:46:42 GMT 2023 , Edited by admin on Fri Dec 15 15:46:42 GMT 2023
|
PRIMARY | |||
|
8929NLK7WN
Created by
admin on Fri Dec 15 15:46:42 GMT 2023 , Edited by admin on Fri Dec 15 15:46:42 GMT 2023
|
PRIMARY | |||
|
6292-91-7
Created by
admin on Fri Dec 15 15:46:42 GMT 2023 , Edited by admin on Fri Dec 15 15:46:42 GMT 2023
|
PRIMARY | |||
|
26174
Created by
admin on Fri Dec 15 15:46:42 GMT 2023 , Edited by admin on Fri Dec 15 15:46:42 GMT 2023
|
PRIMARY | |||
|
m7104
Created by
admin on Fri Dec 15 15:46:42 GMT 2023 , Edited by admin on Fri Dec 15 15:46:42 GMT 2023
|
PRIMARY | Merck Index | ||
|
9978
Created by
admin on Fri Dec 15 15:46:42 GMT 2023 , Edited by admin on Fri Dec 15 15:46:42 GMT 2023
|
PRIMARY | |||
|
27106
Created by
admin on Fri Dec 15 15:46:42 GMT 2023 , Edited by admin on Fri Dec 15 15:46:42 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE |
|
||
|
|
ENANTIOMER -> RACEMATE |
|
||
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|